Weekly Digest – October 2024 Weekly Digest – October 2024 2 Oct 2024: Alentis Therapeutics secures FDA IND approval for ALE.P02, an innovative CLDN1-ADC targeting squamous cancers Alentis Therapeutics announced that the FDA has cleared the IND application for ALE.P02, […]
Weekly Digest – October 2024 Weekly Digest – October 2024 1 Oct 2024: Enhertu receives priority review in the US for HER2-Low and HER2-Ultralow metastatic breast cancer patients previously treated with endocrine therapy Enhertu (trastuzumab deruxtecan) has been granted Priority […]
Weekly Digest – October 2024 Weekly Digest – October 2024 30 Sep 2024: EMA recommends approval of Mirvetuximab Soravtansine for marketing authorization EMA’s CHMP recommended marketing authorization for Mirvetuximab Soravtansine (Elahere), targeting FRα-positive epithelial ovarian, fallopian tube, and primary peritoneal […]
